Details for New Drug Application (NDA): 212689
✉ Email this page to a colleague
The generic ingredient in EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE is emtricitabine; tenofovir disoproxil fumarate. There are eighteen drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the emtricitabine; tenofovir disoproxil fumarate profile page.
Summary for 212689
Tradename: | EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE |
Applicant: | Zydus Pharms |
Ingredient: | emtricitabine; tenofovir disoproxil fumarate |
Patents: | 0 |
Pharmacology for NDA: 212689
Mechanism of Action | Nucleoside Reverse Transcriptase Inhibitors |
Suppliers and Packaging for NDA: 212689
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE | emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 212689 | ANDA | American Health Packaging | 60687-719 | 60687-719-25 | 30 BLISTER PACK in 1 CARTON (60687-719-25) / 1 TABLET, FILM COATED in 1 BLISTER PACK (60687-719-95) |
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE | emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 212689 | ANDA | Redpharm Drug, Inc. | 67296-1830 | 67296-1830-7 | 28 TABLET, FILM COATED in 1 BOTTLE (67296-1830-7) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 200MG;300MG | ||||
Approval Date: | Feb 28, 2020 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 100MG;150MG | ||||
Approval Date: | Jul 1, 2021 | TE: | AB | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 133MG;200MG | ||||
Approval Date: | Jul 1, 2021 | TE: | AB | RLD: | No |
Complete Access Available with Subscription